ACAD Projected Dividend Yield
Acadia Pharmaceuticals Inc ( NASDAQ : ACAD )Acadia Pharmaceuticals Inc. is a biopharmaceutical company. Co. is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. 20 YEAR PERFORMANCE RESULTS |
ACAD Dividend History Detail ACAD Dividend News ACAD Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |